目的探讨乐伐替尼治疗不同类型实体瘤的疗效和安全性。方法通过搜索PubMed,WebofScience,科克伦,CNKI,万方等数据库,所有文献都是关于lenvatinib治疗各种实体瘤的临床疗效比较。根据文献的纳入和排除标准,两名参与者筛选了文献,整理数据并对文献进行评估。采用RevMan5.4软件对纳入文献进行Meta分析。结果共纳入12项研究,包括5213名患者。Meta分析显示,就功效而言,lenvatinib组治疗各种实体瘤延长PFS的风险(HR)是对照组的1.91倍(HR=1.91,95%CI:1.58-2.31,P<0.00001),单一靶向药物组OS延长的风险(HR)是单一靶向药物组的1.27倍(HR=1.27,95%CI:1.15-1.40,P<0.00001)。在安全方面,lenvatinib组治疗各种实体瘤发生不良事件的风险高于对照组,尤其是内分泌毒性,肾/尿毒性,血管毒性,肌肉骨骼/结缔组织毒性和代谢/营养毒性。结论Lenvatinib治疗多种实体瘤可以延长患者的OS和PFS,提高临床获益率,改善患者生活质量。同时,有一定的不良事件发生率,临床用药中应给予对症干预。
UNASSIGNED: The purpose of this study was to investigate the efficacy and safety of lenvatinib in various types of solid tumors.
UNASSIGNED: By searching PubMed, Web of Science, Cochrane, CNKI, Wanfang and other databases, all the literatures about the comparison of clinical efficacy of lenvatinib in the treatment of various solid tumors. According to the criteria of inclusion and exclusion of literature, two participants screened the literature, collated the data and evaluated the literature. RevMan 5.4 software was used for meta-analysis of the included literatures.
UNASSIGNED: A total of 12 studies were included, including 5213 patients. Meta-analysis showed that, in terms of efficacy, the risk (HR) of prolonging PFS in the treatment of various solid tumors in the lenvatinib group was 1.91 times that in the control group (HR = 1.91, 95% CI: 1.58-2.31, p < 0.00001), and the risk (HR) of prolonging OS was 1.27 times that in the single targeted drug group (HR = 1.27, 95% CI: 1.15-1.40, p < 0.00001). In terms of safety, the risk of adverse events in the treatment of various solid tumors in the lenvatinib group was higher than that in the control group, especially in Endocrine Toxicities, Renal/Urinary Toxicities, Vascular Toxicities, Musculoskeletal/a Connective Tissue Toxicities and Metabolism/Nutrition Toxicities.
UNASSIGNED: Lenvatinib in various solid tumors can prolong OS and disease PFS of patients, improve the clinical benefit rate and improve the quality of life of patients. At the same time, there is a certain incidence of adverse events, and symptomatic intervention should be given in clinical medication.